COVID-19 Vaccine Injuries including three myocarditis-induced deaths in New Zealand

The Accident Compensation Corporation (ACC) of New Zealand has accepted 987 claims for injuries relating to the Covid-19 vaccine, and 68% of those are women. Between the beginning of New Zealand’s vaccine program in February 2021 and April 2, 2022, ACC received 2522 claims, with 987 being accepted, and 297 are still pending. During this period, ACC paid out $1.12 million in compensation. 


ACC had accepted 186 claims related to allergic reactions, 103 claims for sprains, 102 claims for contusions.

There were 77 accepted claims for cardiac injury, such as myocarditis or pericarditis.

In terms of age, the group that lodged the greatest number of claims were those in the 45-49 age bracket. Ethnicity data showed 71% of claims lodged with ACC were from Pākehā, and 9% Māori.

Of the 1238 rejected claims, 973 were turned down because ACC deemed there was no injury, and in 119 cases there was no causal link to the vaccine.

Three claims have been made for fatal injury – all due to myocarditis all have been accepted.

The diseased were a female in her 50s, a 26-year-old male and a teenager. 

The death a of 13-year-old child, which has been reported to the coroner, was discussed at length, however further information is required before a determination on the role of the vaccine can be made. A further statement will be made when that information is available.


REFERENCES

ACC accepts 987 vaccine injury-related claims, pays out $1.12m | Stuff.co.nz

Third death considered linked to COVID-19 vaccine | Ministry of Health NZ

Covid-19: Woman with medical issues dies from myocarditis, rare side-effect of Pfizer vaccine | Stuff.co.nz

https://www.health.govt.nz/news-media/media-releases/statement-covid-19-vaccine-independent-safety-monitoring-board

https://www.stuff.co.nz/national/health/coronavirus/300407444/covid19-chief-coroner-says-theres-no-evidence-an-auckland-teenagers-death-was-linked-to-vaccine

https://www.stuff.co.nz/national/health/coronavirus/300564406/covid19-third-death-considered-linked-to-vaccine-was-a-teenager

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative. This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral loads and last for at least 60 da
Read more